SCHEMBL4481328

SCHEMBL4481328

COc1ccc2c(=O)c3ccccc3sc2c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.82
NPC1 O15118 4/20 0.82
RAB9A P51151 4/20 0.82
MAPT P10636 4/20 0.82
KDM4E B2RXH2 4/20 0.82
L3MBTL1 Q9Y468 4/20 0.82
TDP1 Q9NUW8 3/20 0.82
MAOA P21397 2/20 0.54
HPGD P15428 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TSHR P16473 2/20 0.54
MAPK1 P28482 2/20 0.54
TP53 P04637 1/20 0.54
ALOX15 P16050 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
HSD17B10 Q99714 1/20 0.54
HTT P42858 3/20 0.53
NPSR1 Q6W5P4 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30612325 1.00 ALDH1A1 (0.82) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL31037131 1.00 ALDH1A1 (0.82) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL13338880 0.91 KDM4E (0.67) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL30017661 0.91 KDM4E (0.67) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL29372602 0.90 ALDH1A1 (1.00) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL1880565 0.90 ALDH1A1 (1.00) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL29359913 0.90 ALDH1A1 (1.00) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL30567107 0.90 ALDH1A1 (0.65) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL15318110 0.90 ALDH1A1 (0.65) ALDH1A1NPC1RAB9AMAPTKDM4E
SCHEMBL13135135 0.84 ALDH1A1 (0.64) ALDH1A1NPC1RAB9AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834740-B2 Photoactivators THE PROCTER & GAMBLE COMPANY (US) 2017-12-05 US claimed
EP-3097169-A1 CONSUMER PRODUCT COMPOSITIONS The Procter & Gamble Company (US) 2016-11-30 EP claimed
EP-3097176-A1 PHOTOACTIVATORS The Procter & Gamble Company (US) 2016-11-30 EP claimed
EP-3097168-A1 SYSTEMS AND METHODS FOR TREATING A SURFACE The Procter & Gamble Company (US) 2016-11-30 EP claimed
US-20150210964-A1 Consumer Product Compositions THE PROCTER & GAMBLE COMPANY 2015-07-30 US claimed
US-20150210963-A1 Systems and Methods for Treating a Surface THE PROCTER & GAMBLE COMPANY 2015-07-30 US claimed
US-20150210960-A1 Photoactivators THE PROCTER & GAMBLE COMPANY 2015-07-30 US claimed
WO-2015112671-A1 CONSUMER PRODUCT COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2015-07-30 WO claimed
WO-2015112675-A1 PHOTOACTIVATORS THE PROCTER & GAMBLE COMPANY (US) 2015-07-30 WO claimed
WO-2015112667-A1 SYSTEMS AND METHODS FOR TREATING A SURFACE THE PROCTER & GAMBLE COMPANY (US) 2015-07-30 WO claimed
EP-0962826-A1 A positive resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-12-08 EP claimed
US-20260117083-A1 ACTIVE ENERGY RAY-CURABLE INKJET BLACK INK AND PRINTED MATTER ARTIENCE CO., LTD. (JP) 2026-04-30 US disclosed
EP-4733362-A1 ACTIVE ENERGY RAY-CURABLE INKJET INK AND PRINTED MATTER artience Co., Ltd. (JP) 2026-04-29 EP disclosed
EP-3994125-B1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMA (US) 2025-12-24 EP disclosed
WO-2025108852-A1 PROCESS FOR THE PREPARATION OF UNSATURATED ESTERS BASF SE (DE) 2025-05-30 WO disclosed
EP-1270568-A1 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist Biofrontera Pharmaceuticals AG (DE) 2003-01-02 EP disclosed
WO-2002102797-A1 1-METHYL-4-(3-ETHOXY-9H-THIOXANTHENE-9-YLIDENE)-PIPERIDINE AND ITS USE AS 5-HT2B AND/OR H1 ANTAGONIST BIOFRONTERA AG (DE) 2002-12-27 WO disclosed
US-6054501-A CURABILITY; GLOSSINESS; CAN BE BLENDED WITH INKS, PAINTS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2000-04-25 US disclosed
EP-0962826-A1 A positive resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-12-08 EP disclosed
EP-0844255-A1 PHOTOPOLYMERIZATION INITIATOR AND ACTINIC RADIATION-CURABLE COMPOSITION COMPRISING THE SAME NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1998-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117083-A1 ACTIVE ENERGY RAY-CURABLE INKJET BLACK INK AND PRINTED MATTER MAPRE2, MAPRE1, HDLBP ALDH1A1 1414/4885NPC1 2099/4885RAB9A 2098/4885
US-20150210960-A1 Photoactivators NQO1, TYR, CYP1A1 ALDH1A1 78/4885NPC1 3452/4885RAB9A 716/4885
US-20150210963-A1 Systems and Methods for Treating a Surface HMBS, PPOX, TTPA ALDH1A1 1283/4885NPC1 3523/4885RAB9A 3573/4885
US-20150210964-A1 Consumer Product Compositions NQO1, TYR, ETFA ALDH1A1 27/4885NPC1 3810/4885RAB9A 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.